CompletedNot Applicable

Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)

France45 participantsStarted 2016-07-11

Plain-language summary

This study aims to describe quality of life in hereditary or acquired non drug-related bradykinin-mediated angioedema patients, using validated questionnaires

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinically documented angioedema due to C1 inhibitor deficiency, hereditary (type I et II) or acquired * Clinically documented angioedema with normal C1 inhibitor activity (hereditary type III) Exclusion Criteria: * Acquired angioedema with normal C1 inhibitor activity (former "drug-induced") * Minor subjects * Vulnerable subjects (under guardianship/curatorship/tutorship) * Pregnant women

What they're measuring

Dermatology Life Quality Index (DLQI)

Timeframe: 6 months

Angioedema Quality of Life (AE-QoL) Questionnaire

Timeframe: 6 months

Trial details

NCT IDNCT03240991

SponsorCentre Hospitalier Universitaire de Besancon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-12-01

View on ClinicalTrials.gov More Angioedema trials